Jusvinza (CIGB-258) / Center for Genetic Engineering and Biotechnology, Lukang Pharma - LARVOL DELTA

Holguin will be part of a new clinical trial with Jusvinza (Radio Angulo) - "The use of Jusvinza in patients with rheumatoid arthritis with moderate to severe activity left positive experiences in Holguin, for which details are being finalized to carry out a new clinical trial with this biotechnological product....The rheumatologist and head of this service at the Lucía Íñiguez Landín Clinical Surgical Hospital, Alberto Alberteris Rodríguez, said that the Center for Genetic Engineering and Biotechnology reported that a new, more rigorous clinical trial is being planned, designed only for patients in Holguin."

New trial • Rheumatoid Arthritis

Enhancing Wound Healing and Anti-Inflammatory Effects by Combination of CIGB-258 and Apolipoprotein A-I against Carboxymethyllysine Toxicity in Zebrafish: Insights into Structural Stabilization and Antioxidant Properties. (PubMed, Antioxidants (Basel)) - "Additionally, the group treated with apoA-I:CIGB-258 (1:1) demonstrated the lowest plasma levels of total cholesterol (TC) and triglycerides (TG), along with minimal damage to the kidney, ovary, and testicular cells. Conclusively, co-treatment of CIGB-258 with apoA-I effectively mitigated acute inflammation in zebrafish, safeguarded vital organs, structurally stabilized apoA-I, and enhanced HDL functionality."

Journal • Inflammation • APOA1 • IL6

Synergistic Anti-Inflammatory Activity of Lipid-Free Apolipoprotein (apo) A-I and CIGB-258 in Acute-Phase Zebrafish via Stabilization of the apoA-I Structure to Enhance Anti-Glycation and Antioxidant Activities. (PubMed, Int J Mol Sci) - "In conclusion, the co-presence of CIGB-258 ameliorated the beneficial functionalities of apoA-I, such as antioxidant and anti-glycation activities, by enhancing the structural stabilization and protection of apoA-I. The combination of apoA-I and CIGB-258 synergistically enforced the anti-inflammatory effect against CML toxicity in embryos and adult zebrafish."

Journal • Dyslipidemia • APOA1 • IL6

Synergistic Anti-Inflammatory Activity of Apolipoprotein A-I and CIGB-258 in Reconstituted High-Density Lipoproteins (rHDL) against Acute Toxicity of Carboxymethyllysine in Zebrafish and Its Embryo. (PubMed, Pharmaceuticals (Basel)) - "The rHDL containing CIGB-258 enhanced the in vitro antioxidant ability against LDL oxidation, the anti-glycation activity to protect HDL, and the in vivo anti-inflammatory activity against CML toxicity in zebrafish adults and embryos. Overall, incorporating apoA-I and CIGB-258 in rHDL resulted in a synergistic interaction to enhance the structural and functional correlations in a dose-dependent manner of CIGB-258."

Journal • Inflammation • APOA1 • IL6

Alginate Microsponges as a Scaffold for Delivery of a Therapeutic Peptide against Rheumatoid Arthritis. (PubMed, Nanomaterials (Basel)) - "We show that macropores with a size distribution ranging from 50 to 120 nm enabled efficient loading and delivery of a therapeutic peptide (CIGB814), presently under a phase 3 clinical trial for the treatment of rheumatoid arthritis. Alginate microsponges showed 80% loading capacity and sustained peptide release over a few hours through a diffusional mechanism favored by partial erosion of the polymer scaffold. The edible and biocompatible nature of alginate polymers open promising perspectives for developing a new generation of polysaccharide-based carriers for the controlled delivery of peptide drugs, exploiting alternative routes with respect to intravenous administration."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A peptide derived from HSP60 reduces proinflammatory cytokines and soluble mediators: a therapeutic approach to inflammation. (PubMed, Front Immunol) - "Furthermore, it decreases several cytokines and soluble mediators that are raised in RA, as well as decreases the excessive inflammatory response induced by SARS-CoV-2. This approach can be extended to other inflammatory diseases."

Journal • Review • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Novel Coronavirus Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • FOXP3 • HSPD1

CIGB-258 Exerts Potent Anti-Inflammatory Activity against Carboxymethyllysine-Induced Acute Inflammation in Hyperlipidemic Zebrafish via the Protection of Apolipoprotein A-I. (PubMed, Int J Mol Sci) - "Conversely, a co-injection of CIGB-258 or Tocilizumab produced the highest survivability with a normal development speed and morphology. The CIGB-258 group exhibited the smallest IL-6 expression in the liver and the lowest blood triglyceride level. CIGB-258 displayed potent anti-inflammatory activity in hyperlipidemic zebrafish by inhibiting apoA-I glycation, promoting rapid recovery from the paralysis of CML toxicity and suppression of IL-6, and lowering fatty liver changes."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation • APOA1 • IL6

Anti-Inflammatory Activity of CIGB-258 against Acute Toxicity of Carboxymethyllysine in Paralyzed Zebrafish via Enhancement of High-Density Lipoproteins Stability and Functionality. (PubMed, Int J Mol Sci) - "A comparison of efficacy with CIGB-258, Infliximab (Remsima), and Tocilizumab (Actemra) showed that the CIGB-258 group exhibited faster recovery and swimming ability with higher survivability than those of the Infliximab group. The CIGB-258 group and Tocilizumab group showed the highest survivability, the lowest plasma total cholesterol and triglyceride level, and the infiltration of inflammatory cells, such as neutrophils in hepatic tissue. CIGB-258 ameliorated the acute neurotoxicity, paralysis, hyperinflammation, and death induced by CML, resulting in higher survivability in zebrafish and its embryos by enhancing the HDL structure and functionality."

Journal • Hepatology • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pain • Respiratory Diseases • APOA1 • HSPD1

CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. (PubMed, Cell Stress Chaperones) - "Altogether, these results support the therapeutic potential of CIGB-258 for diseases associated with hyperinflammation. Clinical trial registry: RPCEC00000313."

Clinical • Journal • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Novel Coronavirus Disease • Rheumatoid Arthritis • Rheumatology • GZMB • IL10 • IL6 • TNFA

Panama's press highlights medicine achievement in Cuba (Plenglish) - P=NA, N=NA; "The achievement of the CIGB-258 drug in reducing mortality in severe patients by Covid-19 in Cuba....The medicine created and produced by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana allowed 92 percent survival in severe cases and 73 percent of the critics....'These results are really very encouraging, above all because international reports have described that the survival rate of patients on Covid-19 in a critical state does not exceed 30 percent'....The CIGB-258 demonstrated its ability to save lives, because its function is related to the regulation and reduction of inflammatory processes in the patients."

Clinical data • Cytokine storm • Infectious Disease • Novel Coronavirus Disease